A

Amgen

Makes biotech medicines for serious illnesses

Business Performance and Analytics Manager

Full-TimeUpdated on 10/24/2026Deadline 11/5/26
No salary listed
Expert
Hyderabad, Telangana, India
In Person
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • At least 8 years of experience in supply chain, business analytics, data analytics, operations, finance, engineering, or related business functions, or an equivalent combination of education and relevant experience.
  • Experience leading or supervising business analytics, business intelligence, supply chain, planning, or operations teams in a complex global organization.
  • Strong knowledge of end-to-end supply chain planning processes, including Supply Planning, Raw Materials Planning, Inventory Planning, Integrated Business Planning, Manufacturing, Procurement, Logistics, and Site Supply Chain operations.
  • Ability to build collaborative relationships and influence cross-functional stakeholders across global and site organizations to achieve shared business objectives.
  • Experience developing enterprise performance dashboards, KPI frameworks, executive reporting, and business performance scorecards.
  • Knowledge of SAP platforms, including S/4HANA, ECC, Fiori, and IBP, and enterprise reporting and analytics tools.
  • Experience leading process improvement, reporting standardization, automation, and digital transformation initiatives that improve business performance and operational effectiveness.
  • Understanding of data governance, data quality, and master data management principles.
  • Experience partnering with Finance to support business performance reporting, budgeting, forecasting, and operational performance analysis.
  • Ability to translate complex data into meaningful business insights for diverse audiences.
  • Ability to lead teams, develop talent, manage competing priorities, and deliver high-quality results in a fast-paced, matrixed environment.
Responsibilities
  • Serve as the primary integrator of business performance across the Global Planning Network and Site Supply Chain organizations, ensuring a unified view of end-to-end supply chain performance.
  • Build partnerships across Supply Planning, Raw Materials Planning, Digital Technology, and Site Supply Chain teams to align performance measures, priorities, and business objectives.
  • Establish common KPI definitions, reporting standards, and governance processes to create consistency and transparency across global planning and site operations.
  • Connect operational, planning, and financial insights into a cohesive business performance narrative for executive decision-making.
  • Facilitate cross-functional performance reviews to encourage collaboration, identify interdependencies, resolve performance gaps, and drive aligned improvement initiatives across the global network.
  • Ensure analytics and performance reporting support enterprise outcomes across the supply chain.
  • Lead the Business Performance & Analytics team supporting the Global Planning Network and Site Supply Chain organizations.
  • Define the analytics strategy, operating model, priorities, and roadmap aligned with Global Planning objectives.
  • Establish governance for Global Supply Chain Planning KPI reporting, performance management, and business analytics.
  • Ensure timely delivery of recurring and ad hoc reporting.
  • Translate business strategy into meaningful performance metrics and executive dashboards in collaboration with Global Planning.
  • Present business insights and recommendations to Planning and Site Supply Chain leadership to support strategic decision-making.
  • Provide strategic analytics leadership across Supply Planning, Raw Materials Planning, Inventory Planning, and Integrated Business Planning processes.
  • Partner with planning leaders to identify trends, risks, constraints, and opportunities that improve planning performance and supply reliability.
  • Lead analytics supporting manufacturing and site supply chain operations.
  • Ensure consistent reporting and performance visibility across manufacturing sites while standardizing metrics and reporting processes.
  • Lead the design and continuous improvement of enterprise analytics capabilities, including executive dashboards, KPI scorecards, self-service reporting, data visualization, predictive analytics, and AI-enabled decision support.
  • Collaborate with the AIN Global Supply Chain Digital team to develop and support reporting platforms, including Tableau, Power BI, SAP Analytics Cloud, and other enterprise analytics tools.
  • Partner with Digital Technology and SAP teams to prioritize enhancements, improve reporting architecture, and increase automation across supply chain processes.
  • Partner with Finance to improve visibility of supply chain financial performance, including budget tracking, cost center performance, logistics costs, inventory carrying costs, scrap performance, forecast accuracy, and operational cost drivers.
  • Develop analytics that enable proactive financial decision-making and quantify business value delivered through supply chain improvements.
  • Lead initiatives that simplify processes, automate reporting, improve data quality, and standardize analytics across the organization.
  • Champion automation, AI-enabled analytics, predictive modelling, data governance, process standardization, and digital transformation.
  • Drive continuous improvement projects that improve operational efficiency, reporting effectiveness, and business outcomes.
  • Lead and develop the Business Performance & Analytics Analyst team.
  • Prioritize and allocate work across the team to meet business commitments.
  • Build collaborative relationships with planning and site supply chain leaders.
  • Ensure consistent KPI definitions, reporting standards, and data quality across supported functions.
  • Facilitate cross-functional performance reviews and support governance forums.
  • Drive continuous improvement, automation, and analytics capability within the team.
  • Coach and develop team members while fostering a collaborative, customer-focused culture.
Desired Qualifications
  • Experience with Tableau, Power BI, SAP Analytics Cloud, BusinessObjects, SQL, Python, or Databricks.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.